Af­ter sweep of deals in 2023, Gilead to fo­cus on 'late re­search, ear­ly de­vel­op­men­t' pipeline

Gilead is still hunt­ing for deals, par­tic­u­lar­ly in vi­rol­o­gy, on­col­o­gy and in­flam­ma­tion.

Dur­ing Tues­day’s fourth-quar­ter earn­ings call, CEO Daniel O’Day said M&A de­ci­sions will be “dri­ven by the sci­ence,” with a fo­cus on build­ing up the com­pa­ny’s “late re­search, ear­ly de­vel­op­ment pipeline.” He added that the com­pa­ny will con­sid­er lat­er-stage deals “as they fit in­to our port­fo­lio and our range.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.